Other formats:
BibTeX
LaTeX
RIS
@article{1354109,
author = {Szturz, Petr and Specenier, Pol and Van Laer, Carl and Van den Weyngaert, Danielle and Corthouts, Bob and Carp, Laurens and Van Marck, Eric and Vanderveken, Olivier and Vermorken, Jan B.},
article_location = {NEW YORK},
article_number = {6},
doi = {http://dx.doi.org/10.1007/s00405-015-3673-y},
keywords = {Tonsil cancer; Positron emission tomography; Taxanes; Targeted therapy; Epidermal growth factor receptor inhibitor},
language = {eng},
issn = {0937-4477},
journal = {European Archives of Oto-Rhino-Laryngology and Head & Neck},
title = {Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab},
volume = {273},
year = {2016}
}
TY - JOUR
ID - 1354109
AU - Szturz, Petr - Specenier, Pol - Van Laer, Carl - Van den Weyngaert, Danielle - Corthouts, Bob - Carp, Laurens - Van Marck, Eric - Vanderveken, Olivier - Vermorken, Jan B.
PY - 2016
TI - Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab
JF - European Archives of Oto-Rhino-Laryngology and Head & Neck
VL - 273
IS - 6
SP - 1629-1636
EP - 1629-1636
PB - SPRINGER
SN - 09374477
KW - Tonsil cancer
KW - Positron emission tomography
KW - Taxanes
KW - Targeted therapy
KW - Epidermal growth factor receptor inhibitor
N2 - In recurrent head and neck squamous cell carcinoma ineligible for resection or irradiation, treatment aims primarily at symptom control and quality of life enhancement with an expected outcome of 6-12 months. In 2005, a male patient, born in 1944, with a second local recurrence of human papillomavirus negative tonsil cancer was enrolled in the EXTREME trial, and randomized to platinum/5-fluorouracil/cetuximab arm resulting in partial remission with progression-free survival of 12 months. The second-line systemic therapy comprised 5 cycles of 3-weekly docetaxel/cisplatin/5-fluorouracil regimen plus weekly cetuximab. As confirmed on imaging and repeated biopsies, complete response was achieved with disease-free survival of 8 years and follow-up period of 12 years. Severe acute toxicities during the taxane-based chemotherapy plus cetuximab included grade 4 anorexia and grade 3 febrile neutropenia. Poor tumor differentiation, no weight loss, oropharyngeal location, white race, and particularly the induced complete response were most likely the key favorable prognostic factors in the reported patient. The possibility of a synergistic interaction between taxanes and cetuximab should be further explored.
ER -
SZTURZ, Petr, Pol SPECENIER, Carl VAN LAER, Danielle VAN DEN WEYNGAERT, Bob CORTHOUTS, Laurens CARP, Eric VAN MARCK, Olivier VANDERVEKEN and Jan B. VERMORKEN. Long-term remission of locally recurrent oropharyngeal cancer after docetaxel-based chemotherapy plus cetuximab. \textit{European Archives of Oto-Rhino-Laryngology and Head \&{} Neck}. NEW YORK: SPRINGER, 2016, vol.~273, No~6, p.~1629-1636. ISSN~0937-4477. Available from: https://dx.doi.org/10.1007/s00405-015-3673-y.
|
